HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept
View all comments(0)
RemeGen shares plunged 20.9% in morning trading.

RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China.
This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks.
The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Meta Connect 2026 Preview: Phoenix Headset and AI Glasses Take Center Stage, Can Meta Reshape the XR Ecosystem?

Nasdaq Composite Hits Record High; SanDisk Tops $1,900 as Viral Muse Promises to Complete AI Commercialization Loop

Meta Shares Surge Over 8% to Highest Since February as Connect 2026 Nears, Muse Agent May Become New AI Variable

Fed’s Barkin backs rate hike, stays unsure on more increases

Micron Stock Price Forecast: MU Stock Poised to Hit All-Time High as Tight Memory Supply Continues to Support Price Increases






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.